Overview

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Status:
Completed
Trial end date:
2019-11-28
Target enrollment:
Participant gender:
Summary
The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Treatments:
Ozanimod